2024 Scientific Sessions Agenda
Thursday, May 30, 2024 | |
4:00 PM - 6:00 PM |
NLA Opening Session - Exploring Divergent Perspectives on Lp(a) and LDL-C Management Faculty: To Be Announced |
6:00 PM - 7:00 PM | Welcome Reception |
7:15 PM - 9:15 PM |
Non-CME/CE Satellite Symposium This is an independent satellite Non-CME/CE symposium held in conjunction with the NLA 2024 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee. Dinner to be provided by the NLA. |
Friday, May 31, 2024 | ||
7:00 AM - 8:40 AM |
CME/CE Satellite Symposium- Advances in Understanding Lipodystrophy Syndromes: From Rare to Relevant This is an independent satellite CME/CE symposium held in conjunction with the NLA 2024 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee. Breakfast to be provided by the NLA. |
|
8:00 AM - 9:00 AM | Breakfast | |
9:00 AM - 9:10 AM | Opening Remarks | |
9:10 AM - 10:15 AM | Session I — Genetic Basis of Lipid/Lipoprotein Disorders and Cardiovascular Risk: An Expert Panel Discussion | |
Christie M. Ballantyne, MD, FNLA Robert Hegele, MD Daniel J. Rader, MD, FNLA Daniel E. Soffer, MD, FNLA |
||
10:15 AM - 11:00 AM | Session II — Publications from the NLA | |
10:15 AM - 10:20 AM |
Pre-Session Assessment | |
10:20 AM - 10:30 AM | Role of Apolipoprotein B in Clinical Management | Daniel E. Soffer, MD, FNLA |
10:30 AM - 10:40 AM |
A Focused Update to the 2019 NLA Scientific Statement on the Use of Lipoprotein(a) in Clinical Practice |
Christie M. Ballantyne, MD, FNLA |
10:40 AM - 10:50 AM |
Obesity, Dyslipidemia, and Cardiovascular Disease Risk: A Joint Expert Review from the Obesity Medicine Association and the National Lipid Association 2024 |
Harold E. Bays, MD, FNLA |
10:50 AM - 11:00 AM | Post-Session Assessment and Question & Answer Panel | |
11:00 AM - 12:05 PM | Lunch | |
11:00 AM - 11:50 AM | Expert Theaters | |
12:05 PM - 1:30 PM | Session III — Cardiorheumatology | |
12:05 PM - 12:10 PM | Pre-Session Assessment | |
12:10 PM - 12:30 PM |
Fundamentals of Inflammation and Cardiovascular Implications |
Michael Garshick MD |
12:30 PM - 12:50 PM |
Basic and Clinical Science Connecting Psoriasis and Cardiovascular/Cardiometabolic Outcomes |
Joel M. Gelfand, MD, MSCE |
12:50 PM - 1:10 PM | Is Colchicine for ASCVD? Inflammatory Disease? | Vijay Nambi, MD, FNLA |
1:10 PM - 1:30 PM | Post-Session Assessment and Question & Answer Panel | |
1:30 PM - 3:00 PM | Abstract Author Q&A | |
3:00 PM - 4:25 PM |
Session IV — Woman’s Cardiovascular Challenges |
|
3:00 PM - 3:05 PM | Pre-Session Assessment | |
3:05 PM - 3:25 PM | Cardiovascular Concerns in Pregnancy | Jennifer Lewey MD |
3:25 PM - 3:45 PM | PCOS in Adolescents: A Pediatrician’s Challenge | Silva Arslanian, MD |
3:45 PM - 4:05 PM | Menopause | Chrisandra Shufelt, MD |
4:05 PM - 4:15 PM | Dyslipidemia Management in Women of Reproductive Potential: A Clinical Perspective from the National Lipid Association | Anandita Kulkarni, MD |
4:15 PM - 4:35 PM | Post-Session Assessment and Question & Answer Panel | |
6:00 PM - 8:00 PM |
CME/CE Satellite Symposium This is an independent satellite CME/CE symposium held in conjunction with the NLA 2024 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee. Dinner to be provided by the NLA. |
Saturday, June 1, 2024 | ||
8:00 AM - 9:00 AM | Expert Theater(s) | |
8:00 AM - 9:00 AM | Breakfast | |
9:00 AM - 9:10 AM | Opening Remarks | |
9:10 AM - 9:30 AM | NLA Incoming President’s Address | |
Christie M. Ballantyne, MD, FNLA | ||
9:30 AM - 10:05 AM | W. Virgil Brown Distinguished Achievement Lecture | |
Robert A. Hegele, MD | ||
10:05 AM - 11:05 AM | Abstract Author Q&A | |
10:10 AM - 11:00 AM | Non-CME Special Session | |
11:05 AM - 11:55 AM | Session V — Oral Poster Presentations | |
11:05 AM - 11:15 AM | Oral Poster 3 - (141) Obicetrapib Alone and with Ezetimibe Reduces Non-HDL-C by Enhanced LDL-receptor-mediated VLDL Clearance and Increased Net Fecal Sterol Excretion | José Inia, PhD |
11:15 AM - 11:25 AM | Oral Poster 2 - (186) The Long-Term Efficacy and Safety of Evinacumab in Pediatric Patients with Homozygous Familial Hypercholesterolemia | Patrick Moriarty, MD |
11:25 AM - 11:35 AM | Oral Poster 1 - (117) A Randomized, Placebo-Controlled Phase 3 Study of Olezarsen In Patients With Familial Chylomicronemia Syndrome: The Balance Trial | Robert Hegele, MD |
11:35 AM - 11:45 AM | Young Investigator Winner- (200) Pericardial and Pleural Effusions After Evolocumab In a Patient with Severe Familial Hypercholesterolemia | Tia Bimal, MD |
11:45 AM - 11:55 AM | Hunninghake Award Winner | TBD |
11:55 AM- 12:20 PM | NLA Business Meeting and Abstract Awards | |
12:20 PM - 12:50 PM | Late Breakers | |
12:50 PM - 2:00 PM | Lunch | |
12:50 PM - 1:40 PM | Expert Theaters | |
2:00 PM - 3:25 PM | Session VI — From a to B, then Back to LDL: Transatlantic Views on the Lipoproteins that Cause Plaque Jointly Sponsored Session with National Lipid Association and European Atherosclerosis Society |
|
2:00 PM - 2:05 PM | Pre-Session Assessment | |
2:05 PM - 2:17 PM | Disaggregating the Lipid Panel - Why Should I Bother? | Christie M. Ballantyne, MD, FNLA |
2:17 PM - 2:29 PM | Lp(a) - Who to Measure and What to do About it? | Florian Kronenberg, MD |
2:29 PM - 2:41 PM | To ApoB or Not ApoB | Daniel E. Soffer, MD, FNLA |
2:41 PM - 2:53 PM |
LDL-C Lowering Across the Spectrum of Dyslipidemias - Why it Remains the Primary Target |
Professor Kausik Ray, MD |
2:53 PM - 3:03 PM | Panel Discussion | |
3:03 PM - 3:25 PM | Post-Session Assessment and Question & Answer Panel | |
3:25 PM - 3:35 PM | Break | |
3:35 PM - 5:00 PM | Session VII — Make It Happen… | |
3:35 PM - 3:40 PM | Pre-Session Assessment | |
3:40 PM - 4:00 PM | The Community BP Model - Can this be Expanded to Lipids? | Norissa Haynes, MD |
4:00 PM - 4:20 PM | Community Engaged Approaches to Obesity Prevention | Senbagam Virudachalam, MD, MSHP |
4:20 PM - 4:40 PM | Implementing Lipid Management in the Health System - Where We Are and Where We Are Heading | Nihar R. Desai, MD, MPH |
4:40 PM - 5:00 PM | Predicting Risk of Cardiovascular Disease Events (PREVENT) | |
5:00 PM - 5:15 PM | Post-Session Assessment and Question & Answer | |
5:45 PM - 7:00 PM | Honors and Awards Ceremony | |
7:00 PM - 8:00 PM | Foundation of the NLA Event |
Sunday, June 2, 2024 | ||
7:00 AM - 7:45 AM | Zumba with NLA President-Elect Christie M. Ballantyne, MD, FNLA | |
8:00 AM - 9:00 AM | Breakfast | |
9:00 AM - 9:10 AM | Opening Remarks | |
9:10 AM - 10:55 AM | Session VIII — Putting it Together in the Clinic for the Community and the Individual | |
9:10 AM - 9:15 AM | Pre-Session Assessment | |
9:15 AM - 9:35 AM | Treating the Health System | Mary Katherine Cheeley, PharmD, FNLA |
9:35 AM - 9:55 AM | The Adolescent with Moderate-Severe Hypertriglyceridemia and Insulin Resistance | Ann Liebeskind, MD, FNLA |
9:55 AM - 10:15 AM | Differing Treatment Approaches in Underserved Communities - The Contrast of West Philadelphia to Rural New Mexico | Lauren Eberly, MD |
10:15 AM - 10:35 AM | Consultative Cases in Clinical Lipidology | James A. Underberg, MD, MS, MNLA |
10:35 AM - 10:55 AM | Post-Session Assessment and Question & Answer Panel | |
10:55 AM | Adjourn |